Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
2 hedge funds and large institutions have $2K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
33% less capital invested
Capital invested by funds: $3K → $2K (-$1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24 |
Top Sellers
APOPW Hedge Fund Activity: Q2 2019 in Review
2 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q2 2019, worth a combined $2K — down 33% from $3K a quarter earlier.
Fund positioning in APOPW was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $24.
- 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $2K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q2 2019, down 33% quarter-over-quarter.
- 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q2 2019 and 0 closed out.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs buyer in Q2 2019 was Susquehanna International Group, an estimated $24 added.
Based on aggregated 13F filings for Q2 2019.